Using a proteomic approach to screen for new growth factors released by melanoma cells, we identified follistatin as a major heparin-binding factor in medium conditioned by the Bowes melanoma cell line. Since follistatin is primarily studied in relation to its neutralization of activin, a member of the transforming growth factor-b family of ligands, the expression and function of this receptor system was investigated in a panel of melanoma cell lines and melanocytes. All cell lines expressed activin receptors and showed phosphorylation of Smad signal transduction molecules upon treatment with activin. Secretion of follistatin, either native or after retroviral transduction, efficiently prevented Smad activation or activation of an activin-responsive luciferase reporter construct. In melanocytes, activin treatment led to growth inhibition and induction of apoptosis. These effects were counteracted by cotreatment with follistatin. In summary, we characterized the activin-activin receptor system in melanocytes and melanoma cell lines and found that secretion of follistatin by melanoma cells may represent an effective way to circumvent activin's negative regulatory effects.
Using a proteomic approach to screen for new growth factors released by melanoma cells, we identified follistatin as a major heparin-binding factor in medium conditioned by the Bowes melanoma cell line. Since follistatin is primarily studied in relation to its neutralization of activin, a member of the transforming growth factor-b family of ligands, the expression and function of this receptor system was investigated in a panel of melanoma cell lines and melanocytes. All cell lines expressed activin receptors and showed phosphorylation of Smad signal transduction molecules upon treatment with activin. Secretion of follistatin, either native or after retroviral transduction, efficiently prevented Smad activation or activation of an activin-responsive luciferase reporter construct. In melanocytes, activin treatment led to growth inhibition and induction of apoptosis. These effects were counteracted by cotreatment with follistatin. In summary, we characterized the activin-activin receptor system in melanocytes and melanoma cell lines and found that secretion of follistatin by melanoma cells may represent an effective way to circumvent activin's negative regulatory effects.
Introduction
Melanocytes, the pigment-forming cells of the skin, are a quiescent cell population located in the basal layer of the epidermis. Their growth is controlled by an interplay with the surrounding keratinocytes (Meier et al., 1998; La´za´r-Molna´r et al., 2000) . Disturbance of this tight control may result in an imbalance of stimulatory versus inhibitory factors and may represent a first step towards malignant transformation. The transforming growth factor-b (TGF-b) family of growth factors has been described as an important growth-regulatory system in melanocytes. Whereas TGF-b acts as a potent inhibitor of growth and inducer of apoptosis in normal melanocytes, these effects are often much less pronounced, absent or even inversed in melanoma cells (Rodeck et al., 1994 (Rodeck et al., , 1999 Alanko and Saksela, 2000) .
Activins are TGF-b-like dimeric molecules that were initially isolated as stimulators of follicle-stimulating hormone secretion (hence the name) (Ling et al., 1986; Vale et al., 1986) . They consist of two disulfide-linked b subunits, translated from one of three known (A, B or C) human inhibin b gene transcripts, the main activin proteins being the homodimeric activins A and B and the heterodimeric activin AB (Knight, 1996) . They exert their biological effects by interacting with two types of transmembrane serine/threonine kinase receptors (types I and II) . Following binding of the dimeric ligand to two type II receptors (II or IIB), two type I activin-like receptor kinases (ALK4 ¼ activin receptor IB) are recruited and activated by phosphorylation in trans. On their turn, the type I receptors will phosphorylate cytoplasmic Smad proteins (Smad2 and 3) which, after forming a complex with Smad4, will translocate to the nucleus to regulate transcription of activin-responsive genes (Shi and Massague´, 2003) . Activins have been implicated in the control of diverse cellular processes, ranging from tissue patterning during embryogenesis to the control of homeostasis, cell growth and differentiation in multiple adult tissues (Ball and Risbridger, 2001; Luisi et al., 2001; Risbridger et al., 2001; Chen et al., 2002; Welt et al., 2002) . The effects of activin are celltype specific: in some tissues or cell types, it stimulates proliferation, while in others it induces differentiation, growth inhibition and/or apoptosis. Disruption or deregulation of activin signaling is associated with multiple pathological states, including inflammation, reproductive disorders and carcinogenesis Chen et al., 2002; Cho et al., 2003) . Cells may escape from the growth inhibitory effects of activin in several ways: by mutation or downregulation of activin responsive genes or inhibition of their actions or alternatively, by alterations interfering with the activin signal transduction pathway. The latter may occur both by mutations or inhibitory interactions at the receptor level as well as at the level of the Smad signal transduction molecules (Chen et al., 2002) . Alternatively, several factors (inhibins, cripto, follistatin) may interfere with the ability of activin to gain access to and/ or assemble its signaling receptors (Gumienny and Padgett, 2002; Gray et al., 2003) .
Follistatin (FS), a monomeric secreted glycoprotein that binds activin with high affinity, blocks the ability of activin to bind its cell-surface receptors (de Winter et al., 1996) . FS was first isolated from ovarian follicular fluid on the basis of its ability to suppress the secretion of follicle-stimulating hormone from pituitary cells (Robertson et al., 1987; Ueno et al., 1987) , an activity that later was found to be due to the sequestering of activin secreted by these cells (Nakamura et al., 1990) . Up to now, almost all known biological effects of FS are due to its high affinity, nearly irreversible, binding to activin (Nakamura et al., 1990; Schneyer et al., 1994) . Alternative splicing at the 3 0 end of the follistatin gene results in two isoforms, FS-288 and FS-315, the latter having a 27 amino-acid extension at its C-terminus (Shimasaki et al., 1988) . Both contain an N-terminal activin-binding domain and three consecutive 10-cysteine follistatin domains, the first of these containing a lysinerich heparin-binding motif (Wang et al., 2000; Sidis et al., 2001; Innis and Hyvo¨nen, 2003) . FS-288 is primarily bound to cell surface heparan-sulfate proteoglycans, presumably creating a barrier that prevents activin from accessing its receptors (Delbaere et al., 1999; Sidis et al., 2002) and leading to endocytosis and degradation of surface-bound activin (Hashimoto et al., 1997) . FS-315 contains an additional acidic C-terminal tail which interferes to some extent with heparin binding, rendering this the major isoform in solution (Schneyer et al., 1996) . This feature may explain the different potencies of both isoforms in inhibiting the actions of endogenous versus exogenous activin. It is not fully clear what the relative importance of the different isoforms is. Although FS-315 transcripts, in general, are more abundant than FS-288 transcripts, the biologically active form of FS-315 in vivo may be a processed shorter form with properties similar to those of FS-288 (Inouye et al., 1991) .
Based on the identification of FS as a new major heparinbinding factor released by melanoma cells, we characterized the activin/activin receptor system as a new growth factor system in melanoma and melanocytes and investigated the potential role of FS in controlling this system.
Results

Identification of follistatin as a factor secreted by melanoma cell lines
In a screening for new growth factors secreted by melanoma cell lines, conditioned medium (CM) from the Bowes melanoma cell line was prepared, concentrated 50 times, and subjected to a triple precipitation procedure using heparin beads in order to deplete it from heparin-binding factors. The initial and depleted concentrated CM and the resulting heparin-binding fraction were subjected to gel electrophoresis, followed by protein silver staining of the gel. This resulted in a very similar pattern of proteins in the concentrated CM and in the depleted concentrated CM, indicating that the vast majority of secreted proteins did not bind to the heparin beads (Figure 1a, lanes 1 and 2) . However, a band at 745 kDa (indicated with an asterisk) was not present in the depleted CM. This band corresponded with the major band found in the heparin-binding fraction (Figure 1a, lanes 3 and 4) . N-terminal sequencing identified this band as FS. The sequence obtained, GN(C)WLRQA, represents the N-terminus of mature FS after cleavage of its precursor form Robertson et al., 1987; Ueno et al., 1987; Nakamura et al., 1990) (Figure 1b ). To ascertain that this major band is due to FS and does not represent a major other, N-terminally blocked protein, we performed an in-gel digestion of this band, using trypsin. The resulting peptides were extracted and then submitted to mass spectrometric analysis. This confirmed that the major heparin-binding factor released by Bowes melanoma cells was indeed FS (Figure 1b) . Western blotting and immunostaining with an anti-FS antibody confirmed the presence of FS in concentrated Bowes melanoma CM, but not in concentrated CM depleted of heparin-binding factors (Figure 1c ). To verify whether the different molecular weight forms recognized by the antibody represent different FS isoforms or result from differential post-translational modifications (glycosylation, Cterminal processing), the Bowes melanoma cell line was treated for 24 h with the glycosylation inhibitor tunicamycin before harvesting the CM. Subsequent immunostaining of this concentrated CM with an anti-FS antibody revealed only one, faster migrating band (Figure 1d) , meaning that the different bands seen in CM from the Bowes melanoma cell line represent differentially glycosylated forms of one FS isoform. As the tryptic peptides that had been identified by mass spectrometry did not allow us to conclude which isoform (FS-288 or FS-315) was produced by these cells, we focused further on the tryptic fragment that would be obtained from the C-terminus. However, although we screened specifically for masses of potential C-terminal peptides by mass spectrometry, we could not identify this peptide. This may be due to the highly hydrophilic nature of the C-terminus or, alternatively, may mean that the C-terminus of mature FS is close to the last trypsin cleavage site, and would thus give rise to a peptide that is too small to be detected.
As an alternative approach to identify which FS isoform was produced, RT-polymerase chain reaction (PCR) was performed. A primer set was designed such that different lengths of amplification products were obtained, depending on the isoform present. This primer set was used to amplify cDNA from Bowes melanoma cells, melanocytes and melanocytes that had been cultured in the presence of the phorbolester PMA, a known upregulator of FS (Tano et al., 1995) . As compared to nonstimulated melanocytes, high FS-315 mRNA levels were found in Bowes melanoma cells and in melanocytes cultured in the presence of PMA. In all cases, only an amplification product derived from the FS-315-encoding mRNA was obtained (Figure 1e ). This isoform has been described to be the major FS isoform in solution (in contrast to FS-288, which is primarily cell surface bound), consistent with our isolation of FS as a factor secreted in the medium.
To verify whether FS production was also seen in other melanoma cell lines, we analysed concentrated CM from a panel of melanoma cell lines by Western blotting (Figure 1f ). This revealed that, albeit lower than was found for the Bowes melanoma cell line, FS secretion was easily detectable in several cell lines (530, A375, DX3), whereas lower (FM45, FM87, HMB2) to faint signals were obtained in others (e.g. FM3/P, MeWo). None of the cell lines accumulated higher FS levels than those found for the Bowes melanoma cell line. Also here, RT-PCR analysis learned that FS-315 was the only isoform produced by melanoma cells (data not shown). In conclusion, several melanoma cell lines release FS-315, either as a full-length or a C-terminaltruncated form, in their medium.
Expression of activin and activin receptors in melanoma cell lines
Since nearly all known effects of FS are mediated via its binding to and neutralization of activin, we first characterized whether activin can act on melanoma cells. Therefore, we performed RT-PCR for activin receptors I, IB, II and IIB. Of these, activin receptors IB and IIB were highly expressed in all melanoma cell lines and melanocytes ( Figure 2 ). To verify whether activin and inhibin were produced by melanocytes and the melanoma cells, we performed RT-PCR for the inhibin a-subunit and the b A , b B and b C subunits (Figure 2 ). This revealed a high expression of the b A subunit in the majority of the melanoma cell lines, suggesting that activin A, a homodimer of two b A subunits, is the major activin expressed in this type of cells. Melanocytes cultured in the presence of PMA had higher mRNA levels of inhibin-a, -b A and -b B , consistent with the PMA-induced upregulation of activin expression and secretion in a variety of cells (Cho et al., 2003) . To quantify activin A secretion by the melanoma cells, we set up an ELISA, which allowed us to detect activin A levels as low as 0.25 ng/100 ml. When 25-fold concentrated CM of the melanoma cell lines was tested in this ELISA, no specific signal could be obtained, meaning that activin A levels in the melanoma cell lines do not exceed 0.1 ng/ml (data not shown). Using a similar ELISA to detect FS, a signal was easily obtained using crude CM from the Bowes melanoma and FS-transduced FM3/P cell lines, whereas vector-transduced FM3/P cells were completely negative (data not shown). These data suggest that activin A is secreted in only very low amounts by the melanoma cells, or may remain cellsurface associated, leading to residual levels in the medium, or may, in contrast to FS, be subject to fast proteolytical breakdown. The follistatin/activin system in human melanoma C Stove et al
Activin-induced Smad-phosphorylation in melanoma cell lines
Receptor activation by members of the TGF-b family of growth factors is typically followed by activation (phosphorylation) of receptor Smads (Shi and Massague´, 2003) . Using a phospho-Smad-specific antibody, we determined whether the addition of activin indeed resulted in activation of Smads in the cells. We therefore added activin to serum-free medium or to medium conditioned for 48 h by the melanoma cell lines. Positive and negative controls, respectively, were the human breast cancer cell line MCF-7 (Liu et al., 1996) and the human colon cancer cell line HCT-8, the latter having a nonsense mutation in activin receptor II (Hempen et al., 2003) (Figure 3, upper panel) . Note that basal Smad activation levels seen in Figure 3 should not be compared between cell lines, since differences in band intensities between blots may be the result of different film exposure times. When activin was added in fresh serum-free medium, Smad phosphorylation increased in all melanoma cell lines tested, meaning that the first steps of the activin signal transduction (receptor binding and activation of signal transduction molecules) remained intact (Figure 3 , middle panel, last two lanes). Of note, the Smad activation observed was much more pronounced than that seen in treated MCF-7 breast cancer cells, possibly due to the higher receptor levels in all of the melanoma cell lines (Figure 2 ). Smad phosphorylation following activin treatment in fresh, serum-containing medium was also seen in melanocytes ( Figure 3 , lower panel, last two lanes). Here, serum starvation was omitted, since the majority of melanocytes does not survive, or goes into apoptosis, after a 48-h serum depletion (unpublished observations). To verify whether the presence of secreted factors influences the response of the cells, activin was added to medium conditioned by the cells. In several melanoma cell lines, this resulted in a lower (e.g. A375, DX3) or even completely absent (Bowes) Smad activation, when compared to activin treatment in fresh medium ( Figure 3 , first two lanes). This means that, although these cell lines have retained the intrinsic capacity to respond to activin in terms of Smad activation, the secretion of (an) inhibitory factor(s) prevents this activation. Since the prevention of Smad activation following activin treatment in the CM correlated well with the presence of FS in this CM (Figure 1f ), the action of FS, secreted by melanoma cells, was further investigated.
Follistatin-315 secretion by melanoma cell lines inhibits activin-induced Smad activation
In the Bowes melanoma cell line, secreting the highest amounts of FS (Figure 1f ), Smad phosphorylation was not altered upon addition of activin to the CM (Figure 3 and 4a). We therefore chose this cell line to provide further evidence that activin's stimulatory effects are indeed blocked by secretion of FS into the medium. Bowes melanoma cells were first washed extensively before the addition of activin to CM or to fresh medium. When administered in the CM, activin treatment did not lead to an increase in Smad phosphorylation, irrespective of whether (Figure 4a , lanes 3 and 4) or not (lanes 1 and 2) the cells had been washed before the treatment. Addition of activin to serum-free medium that was added to washed cells did result in increased Smad The follistatin/activin system in human melanoma (Figure 4c ). Owing to this secretion, we reasoned that further sorting of these cell lines would not be necessary to investigate its effects: FS produced by the transduced cell lines was likely to protect nontransduced cells as well. No differences in morphology or growth could be observed between the two transduced populations, either in the presence or absence of activin (data not shown). When tested for Smad activation, both the empty-vector-and FS-transduced FM3/P and MeWo cell lines were responsive to activin, when added in serum-free medium (Figure 4d , lanes 5 and 6). However, similar to what was observed in the Bowes melanoma cell line, no increase in Smad activation occurred when activin was added immediately to FS-transduced cells (lanes 1 and 2) or, alternatively, was added to 48-h conditioned medium that was added to washed cells (lanes 3 and 4). T his contrasts with the empty-vector-transduced cells, which were still fully responsive to activin (lanes 1, 2 and 3, 4). In agreement with this, treatment of washed Bowes melanoma cells with activin in CM from FM3/P FS did not lead to increased Smad activation (Figure 4e , lanes 5 and 6), in contrast to its addition in fresh serum-free medium or in CM from FM3/P LIE (lanes 1, 2 and 3, 4). In conclusion, FS secretion by melanoma cells is an effective way to prevent Smad activation by activin.
Follistatin secretion by melanoma cell lines inhibits their response to an activin-responsive reporter gene construct
Since the activation of receptor-Smads does not necessarily mean that the signal will lead to alterations in gene transcription, we performed luciferase-reporter assays using the TGF-b-and activin-responsive CAGA promoter construct (Dennler et al., 1998) . Activin treatment of FM3/P cells resulted in a twofold increase In (e), also non-self serum-free CM was used
The follistatin/activin system in human melanoma C Stove et al of luciferase activity that could be completely inhibited by the addition of exogenous FS (Figure 5a ). When the transduced cells were tested, a similar increase was seen in empty-vector-transduced cells, whereas the FStransduced FM3/P cells did not show any increase in promoter activity (Figure 5b ). This confirms the results of Smad activation and, again, shows that the secretion of FS by melanoma cells is an effective mechanism to neutralize the effects of activin.
Activin inhibits melanocyte growth and induces apoptosis
Since TGF-b has been described as a proapoptotic and growth-inhibitory factor for melanocytes, we addressed the question whether activin may have similar effects. Melanocytes cultured in the presence of activin showed a marked decrease in growth, as measured by mitochondrial activity using the MTT assay ( Figure 6a ). This decrease could be counteracted in a dose-dependent way by cotreatment with FS, which, when administered alone, did not have an effect on the growth of melanocytes. To verify whether an increase in apoptosis can provide an explanation for the observed decrease in growth, we performed Annexin V labeling of serum-starved melanocytes that were treated or not with activin. Annexin V has a high affinity for phosphatidylserine, which is exposed at the outer surface of the cells in early apoptosis. Deprivation of melanocytes from growth factors readily renders them susceptible to apoptosis. As is evident from Figure 6b , a 20-h treatment with activin results in a significant increase in apoptosis, thus providing a likely explanation for the decreased 'growth' observed, as measured by mitochondrial activity. Again, this effect could be counteracted by coadministering FS. In conclusion, FS protects melanocytes against growth inhibition by activin, at least partly, by counteracting its proapoptotic effects.
Discussion
Although TGF-b-like molecules have been studied for more than a decade in melanocytes and their malignant derivatives, surprisingly, only the roles of TGF-b itself have been looked at (Rodeck et al., 1994 (Rodeck et al., , 1999 Alanko and Saksela, 2000) . In the present paper, based on the identification of FS as a major heparinbinding growth factor released by melanoma cells, we studied the activin/FS system as a new regulatory growth factor system in melanocytes and melanoma cell lines. Melanocytes are neural crest-derived cells that migrate to the skin during an early stage of development. They form a quiescent population in the basal layer of the epidermis, making extensive contacts with the surrounding keratinocytes, to which they deliver melanin. Conversely, keratinocytes are crucial in controlling normal proliferation of melanocytes. They do so in a contact-dependent manner by the formation of Ecadherin-mediated adherens junctions with the melanocytes, necessary for and leading to the formation of gap junctions (Meier et al., 1998) . A delicate balance exists between stimulatory and inhibitory factors, released either by the melanocytes themselves or by the keratinocytes. Loss of control of keratinocytes over melanocytes may thus be the result of altered cell-cell adhesion and/or alterations in growth factor systems in either of both partners. A shift in the balance between positive (basic fibroblast growth factor, insulin-like growth factor-I, heregulin, etc.) and negative (TGF-b, interleukin-6, etc.) regulators of melanocyte growth may represent a first step towards uncontrolled proliferation (La´za´r-Molna´r et al., 2000; Stove et al., 2003a) . Here, we have shown that activin may serve as a novel negative regulatory factor controlling melanocyte proliferation. Exogenous activin is able to inhibit proliferation and induce apoptosis in primary melanocytes. These effects resemble those of TGF-b (Alanko and Saksela, 2000) . In vivo, activin may be provided by the keratinocytes, Figure 6 Follistatin counteracts activin-mediated growth inhibition and apoptosis in melanocytes. (a) Growth, relative to untreated cells, as measured by MTT assay. Melanocytes were treated for 4 days with activin (25 ng/ml) and the indicated concentration of follistatin. (b) % Annexin V positivity of serumstarved melanocytes that have been treated for 20 h with activin (25 ng/ml) and/or follistatin (400 ng/ml). Asterisks indicate means that differ significantly (Po0.05) from control Figure 5 Follistatin prevents activin-mediated induction of a luciferase reporter construct. Activin (25 ng/ml) and/or follistatin (100 ng/ml) was added for 30 min to the indicated melanoma cell lines that had been transiently transfected with a b-galactosidase reporter construct and a luciferase-reporter construct with an activin-responsive promoter (open bars), without a promoter (black bars) or with a constitutively active promoter (gray bars). Bars represent normalized luciferase activities, relative to untreated cells. In (a), a representative experiment is shown, in (b), the asterisk indicates that the mean is significantly larger than the control (Po0.05)
The follistatin/activin system in human melanoma C Stove et al which are known producers of this molecule (Beer et al., 2000) . Using transgenic mice, a role for keratinocytederived activin in the skin has been shown to exist in wound healing processes and in the regulation of cell matrix deposition (Munz et al., 1999; Wankell et al., 2001b) . Although, in vitro, keratinocyte proliferation was shown to be decreased by activin, no decreased keratinocyte proliferation was observed in vivo, possibly because of the induction by activin of other factors that may act as prosurvival factors for the keratinocytes (Beer et al., 2000) . Here, we found that both melanocytes and melanoma cells express mRNA for inhibin b subunits, primarily the bA subunit, presumably leading to the formation of the homodimeric activin A. Expression of this bA subunit was markedly higher in melanocytes cultured in PMA-containing medium, consistent with the fact that PMA is a known inducer of activin (Cho et al., 2003) . However, surprisingly, measurement of activin A levels in melanoma CM revealed that activin A levels in none of the melanoma cell lines exceeded 0.1 ng/ml. Although it is possible that melanoma cells indeed secrete only residual amounts of activin A, we cannot exclude that it is rapidly degraded, or alternatively, remains associated with the cell surface, prohibiting measurement in the CM. Therefore, although several of the melanoma cell lines had higher expression of the bA subunit, when compared to the levels found in non-PMA treated melanocytes, a role for activin in melanomagenesis, as has been proposed for TGF-b (Shellman et al., 2000; Berking et al., 2001) , remains speculative. Further in vitro and in vivo experiments, using activin-transduced cells, are needed to clarify this issue.
Early in malignant transformation, it is crucial for the survival of transformed cells to profit optimally from mitogenic stimuli, while escaping from inhibitory signals. Overexpression or mutation of receptor systems, or the gain of autocrine loops, may contribute to the first, while downregulation of inhibitory receptors or the secretion of ligand traps have been shown to contribute to the latter (Massague´and Chen, 2000; Blume-Jensen and Hunter, 2001; Gullick, 2001 ). Since activin acts as an inhibitory molecule for melanocytes, neutralization of its effects implies the release from a negative regulatory factor. As shown here, one way to do so is the production and secretion of FS. By binding to activin, FS sequesters it in the medium and prevents it from accessing its cell surface receptors. As a result, although these cell lines have an intact signaling machinery, no signaling occurs when activin is added to medium in which these cells have released FS previously. A similar activin-inhibitory effect has been described for the more recently described follistatinrelated protein FLRG/FSTL3 . Using RT-PCR, we found transcripts of the latter in melanocytes and in all melanoma cells (data not shown). However, we consider it unlikely that follistatin-related protein would play a major role in our system, since (1) no correlation could be found between its expression and the activin responsiveness of the cells, with FLRG/ FSTL3-expressing cells still being fully responsive when activin was administered in their CM and (2) FLRG/ FSTL3 lacks a heparin-binding site, while the activinneutralizing effect of our CM can be abolished by depleting it from heparin-binding factors. FS is a known target gene of the canonical Wnt signaling pathway, in which b-catenin translocation to the nucleus results in transcriptional activation of target genes (Willert et al., 2002) . In cancer, including melanoma, b-catenin mutations may lead to constitutive activation of this pathway, resulting in aberrant activation of these target genes (Rubinfeld et al., 1997) . However, examination of b-catenin localization in our panel of melanoma cell lines did not reveal obvious nuclear b-catenin localization in any cell line (data not shown). Other factors capable of regulating FS secretion include retinoic acid, prostaglandin E 2 , activators of protein kinase A and C, as well as growth factors such as keratinocyte growth factor and epidermal growth factor (Michel and Farnworth, 1992; Wankell et al., 2001a) . Interesting in this respect is our recent identification of a potent autocrine loop of heregulin, an epidermal growth factor-like ligand, in the Bowes melanoma cell line, which secretes the highest amounts of FS (Stove et al., 2003a) . Whether there is a crosstalk between receptor tyrosine kinase pathways and regulation of FS expression in melanoma cell lines is currently being investigated. We could not find a clear correlation between FS expression and the differentiation status of the cell lines in our panel: FS secretion was both present in cell lines that had lost several melanocytic markers (e.g. Bowes melanoma, A375 and DX3) as in cell lines that retained, at least partly, markers of differentiation (e.g. the pigmented 530 and FM87).
Surprisingly, although the first steps in the activin signaling pathway were intact in all cell lines tested, none of the melanoma cell lines showed significant growth inhibition following activin treatment, in contrast to what was seen for melanocytes. Several explanations may account for this. Important for activin's growth-inhibitory effects is the modulation of genes involved in cell-cycle regulation (Chen et al., 2002) . These genes are frequently mutated in melanoma (Bartkova et al., 1996) . Alternatively, activation of the MAPK pathway, either by mutation of signaling molecules (N-ras and B-raf) (Davies et al., 2002; Tuveson et al., 2003) or by autocrine loops (La´za´r-Molna´r et al., 2000; Stove et al., 2003a) was shown to be of major importance in many melanomas. Constitutive activation of this pathway was shown to result in insensitivity to growth inhibition by TGF-b, while still allowing other effects of these molecules to occur (Shellman et al., 2000) .
In conclusion, the effects of the activin-follistatin system in melanoma may be dual: while early in progression the secretion of FS may be crucial as a protection against activin's inhibitory effects, cells in a later stage may use activin -either autocrine or paracrine -to maintain a state of dedifferentiation and to create a supportive microenvironment. It will be important to determine the presence of this growth factor system in tumor samples from melanoma patients
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Materials and methods
Cell lines
The cell lines were obtained and cultured as described before (Stove et al., 2003a) . Epidermal melanocyte primary cultures were obtained from neonatal foreskins and established in M199 medium (Gibco BRL, Merelbeke, Belgium), supplemented with 2% fetal bovine serum, 10 À9 M cholera toxin, 10 ng/ml basic fibroblast growth factor, 10 mg/ml insulin, 1.4 mM hydrocortisone and 10 mg/ml transferrin (all from Sigma, Bornem, Belgium). Postprimary cultures were maintained in low-calcium (0.03 mM) M199 medium, supplemented with the same factors and 10% fetal bovine serum. The melanocytic origin of all melanoma cell lines was checked by immunocytochemistry using two melanoma-specific antibodies, HMB45 (Enzo Diagnostics, Farmingdale, NY, USA) and NKI/C3 (Biogenex, San Ramon, CA, USA). All melanoma cell lines were positive for at least one of these markers (data not shown). As most of the experiments were carried out with Bowes melanoma cells, which were only positive for NKI/C3, additional electron microscopy was performed to confirm the presence of premelanosome-like structures in this nonpigmented cell line (data not shown).
Antibodies and reagents
Primary antibodies used were mouse monoclonal anti-follistatin (R&D Systems, Abingdon, UK) and rabbit polyclonal anti-phospho-Smad 2 (Cell Signaling Technology, Beverly, MA, USA). Recombinant activin and follistatin were purchased from R&D Systems, tunicamycin was obtained from Sigma.
Preparation of CM
Subconfluent monolayers were washed three times with phosphate-buffered saline (PBS), incubated for 24 h with serum-free medium, washed again three times with PBS, followed by a 48 h incubation with serum-free medium. The latter was cleared from cells by a 5-min centrifugation step at 250 g. The resulting supernatant was centrifuged for an additional 20 min at 2000 g to remove cell debris, filtered through a 0.2 mm filter, and stored at À201C until use. To isolate the heparin-binding fraction from the CM, the latter was depleted from heparin-binding factors by triple precipitations with heparin beads (Bio-Rad, Hercules, CA, USA). Elution of the heparin-binding fraction was carried out with 1 M NaCl, followed by desalting using Microcon filters.
Western blotting
All lysates were made from cell cultures of approximately 90% confluence. For phosphorylation experiments, cells were washed three times with PBS and serum starved for 48 h. Then, the cells were treated without washing or, alternatively, after washing three times with PBS. Immediately after the treatments, the cells were washed three times with PBS before lysis with PBS containing 1% Triton X-100, 1% Nonidet P-40 (Sigma) and the following protease inhibitors: aprotinin (10 mg/ml), leupeptin (10 mg/ml) (ICN Biomedicals, Costa Mesa, CA, USA), phenylmethylsulfonyl fluoride (1.72 mM), NaF (100 mM), NaVO 3 (500 mM) and Na 4 P 2 O 7 (500 mg/ml) (Sigma). After clearing the lysates, protein concentration was determined using the Rc Dc Protein Assay (Bio-Rad), and samples were prepared such that equal amounts of protein were to be loaded. Sample buffer (Laemmli) with 5% 2-mercaptoethanol and 0.012% bromophenol blue was added, followed by boiling for 5 min and separation of the proteins by gel electrophoresis on 8 or 12% polyacrylamide gels and transfer onto a nitrocellulose membrane (Amersham Pharmacia Biotech, UK). Quenching and immunostaining of the blots was performed in 5% nonfat dry milk in PBS containing 0.5% Tween-20. The membranes were quenched for 30 min, incubated with primary antibody for 2 h, washed four times for 5 min, incubated with horseradish peroxidase-conjugated secondary antibody for 30 min, and washed five times for 5 min. Detection was carried out using enhanced chemiluminescence reagent (Amersham Pharmacia Biotech) as a substrate. To control for equal loading of total lysates, immunostaining with anti-tubulin antibody was performed routinely (not shown).
N-terminal sequencing and mass spectrometry
N-terminal sequence analysis of a PVDF electroblotted sample was performed on a 476A Protein sequencer. For mass spectrometric analysis, the gel slice containing the band of interest was excised and washed twice with 200 mM ammonium bicarbonate in 50% acetonitrile/water (20 min, at 301C), and allowed to dry at room temperature. The tube was then chilled on ice and 8 ml of digestion buffer (50 mM ammonium bicarbonate, pH 7.8) containing 150 ng of modified trypsin was added. The sample was kept on ice for 45 min, after which 15 ml of digestion buffer was added, followed by overnight incubation at 371C. The supernatant was recovered, and the peptides were extracted from the gel piece by washing twice with 60% acetonitrile/0.1% formic acid in water. The extracts were then combined, followed by drying in a Speedvac centrifuge. The sample was dissolved in 0.1% formic acid and injected in an automated nano-HPLC system (Dionex) (Devreese et al., 2002) . The separated peptides were detected on-line by an ESI-Q-TRAP mass spectrometer (Applied Biosystems/MDS Sciex, Concord, ON, Canada) (Hager, 2002) , equipped with a nanospray ion source (Protana, Odense, Denmark). In this method, an automated MS to MS/MS switching protocol was used for LC-MS/MS analysis of the peptides (Sandra et al., 2004) . Briefly, first an enhanced MS scan as survey scan (m/z 400-1500), followed by an enhanced resolution scan of the two most intense ions was performed. If their charge state was þ 2 or þ 3, an enhanced product ion scan (MS/MS) of these ions was performed. The total cycle time of this set-up was approximately 4.5 s.
RT-PCR
Total RNA was extracted from approximately 5 Â 10 6 cells using the Qiagen RNEASY kit (Qiagen, Chatsworth, CA, USA). In total, 1 mg of total RNA was reverse-transcribed with oligo-dT primers using the Qiagen RT kit (Qiagen) according to the manufacturer's instructions. PCR was performed on 250 ng template cDNA using the Qiagen Taq PCR kit (Qiagen) according to the manufacturer's instructions. Reactions were carried out in a Minicycler (Biozym, The Netherlands) with an initial denaturation at 941C for 3 min, 35 cycles of 941C for 50 s (denaturation), 611C for 50 s (annealing), and 721C for 1 min (elongation), followed by a final extension at 721C for 10 min. Table 1 lists the primers that were used.
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Retroviral transduction
FS315 was Tsp509I digested from the FS315 plasmid construct, pSV2HF-315 (Inouye et al., 1991) , and EcoRI subcloned into the retroviral vector LZRS-IRES-EGFP. This control vector expresses only EGFP from an IRES. The production of retroviral supernatant was carried out as described before (Stove et al., 2003b) . Briefly, the PhoenixAmphotropic packaging cell line (a kind gift from Dr GP Nolan, Stanford University School of Medicine, Stanford, CA, USA) was transfected with the LZRS-IRES-EGFP control vector, or with LZRS-FS315-IRES-EGFP, by using calciumphosphate precipitation (Invitrogen, San Diego, CA, USA) to generate the retrovirus. The retroviral supernatant was spun (10 min for 350 g) and aliquots were stored at À701C until use. For transduction of cell lines, cells were mixed with retroviral supernatant that was incubated for 10 min with Dotap (Roche Molecular Biochemicals, Mannheim, Germany). To increase transduction efficiency, cells were spun (90 min, 950 g, 321C). Transduction efficiency was evaluated by flow cytometry.
Cell proliferation assay
A total of 12 500 melanocytes were seeded into the wells of a 96-well plate in 100 ml DMEM medium containing 10% fetal bovine serum. After 24 h, the cells were washed twice with serum-free DMEM and then treated with 200 ml serum-free medium, supplemented with growth factors as indicated. After 4 days, metabolic activity was measured with a colorimetric assay, using 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma), as described before (Stove et al., 2003a) .
Annexin V staining
150 000 melanocytes were seeded in the wells of a 24-well plate in 1 ml DMEM medium containing 10% fetal bovine serum. After 24 h, the cells were washed twice with serum-free DMEM and then treated for 20 h with 500 ml serum-free medium, supplemented with growth factors as indicated. After detaching the cells, Annexin V staining and flow cytometric analysis were performed as described before (Stove et al., 2003a) .
Luciferase reporter assay
A total of 100 000 cells were seeded per well of a 24-well plate. After 24 h, cells were transfected with 300 ng of pGL3basic, pGL3 control (Promega) or the CAGA luciferase reporter construct (Dennler et al., 1998) , together with 100 ng pUT b-galactosidase reporter construct to normalize for transfection efficiencies. Some 24 h after transfection, cells were treated, or left untreated, for 20 h, after which they were lysed. After freezing the lysates for 1 h at À801C and thawing, they were cleared from debris by centrifugation and used for measuring luciferase-and b-galactosidase activities.
Statistics
Differences between means were considered as significant when the P-value was o0.05, using Student's t-test.
Abbreviations CM, conditioned medium; EGFP, enhanced green fluorescence protein; FS, follistatin; IRES, internal ribosomal entry site; LIE, LZRS-IRES-EGFP; PMA, phorbol 12-myristate 13-acetate; TGF-b, transforming growth factor-b. Depending on the isoform, the primer set for FS gives rise to a PCR amplification product of 114 (for FS-315) or 378 (for FS-288) base pairs
